Abstract
The recent study by Timmers et al. (1) is a valuable randomized, double-blind, crossover clinical trial involving patients with well-controlled type 2 diabetes who were assigned to receive placebo and 150 mg/day resveratrol for 30 days to evaluate insulin sensitivity via hyperinsulinemic-euglycemic clamp. After the intervention, the authors found that hepatic and peripheral insulin sensitivity were not affected by the resveratrol treatment, and additionally, no significant changes in intrahepatic lipid content were found. However, the authors found an increase in intramyocellular lipid content in type 2 muscle fibers, a tendency for blood pressure to decrease, and an improvement of ex vivo mitochondrial function. The authors concluded …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
